董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
J. David Joyner President and Chief Executive Officer and Director 60 1780.88万美元 未持股 2025-05-15
Guy Sansone Director 60 16.75万美元 未持股 2025-05-15
Alecia A. DeCoudreaux Director 70 33.50万美元 0.30 2025-05-15
Leslie Norwalk Director 59 16.75万美元 未持股 2025-05-15
Larry Robbins Director 55 16.75万美元 未持股 2025-05-15
Doug Shulman Director 57 16.75万美元 未持股 2025-05-15
Anne M. Finucane Director 72 33.50万美元 3.24 2025-05-15
Fernando Aguirre Director 67 36.00万美元 3.28 2025-05-15
Roger N. Farah Executive Chair 72 30.50万美元 0.41 2025-05-15
C. David Brown II Director 73 35.50万美元 11.91 2025-05-15
Michael F. Mahoney Director 60 33.50万美元 0.22 2025-05-15
J. Scott Kirby Director 57 33.50万美元 0.27 2025-05-15
Jeffrey R. Balser Director 63 34.83万美元 0.51 2025-05-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
J. David Joyner President and Chief Executive Officer and Director 60 1780.88万美元 未持股 2025-05-15
Heidi B. Capozzi Executive Vice President and Chief People Officer 55 未披露 未持股 2025-05-15
James D. Clark -- Senior Vice President and Controller and Chief Accounting Officer 60 未披露 未持股 2025-05-15
Prem Shah -- Executive Vice President and Group President 45 1326.59万美元 3.47 2025-05-15
Tilak Mandadi Executive Vice President, Ventures and Chief Digital, Data, Analytics and Technology Officer 61 1136.13万美元 2.02 2025-05-15
Thomas F. Cowhey Executive Vice President and Chief Financial Officer 53 764.44万美元 2.86 2025-05-15
Roger N. Farah Executive Chair 72 30.50万美元 0.41 2025-05-15
Steven H. Nelson Executive Vice President and President 66 未披露 未持股 2025-05-15
Samrat S. Khichi Executive Vice President, Chief Policy Officer and General Counsel 58 1188.65万美元 0.98 2025-05-15

董事简历

中英对照 |  中文 |  英文
J. David Joyner

J. David Joyner,自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官;从2023年1月到2024年10月,担任Cvs Health Corporation的执行副总裁兼药房服务总裁;从2021年7月到2023年9月担任健康技术公司gWell, Inc.的战略业务顾问;从2020年9月到2023年1月,担任Podimetrics Inc.(一家专注于糖尿病足溃疡识别和治疗的医疗保健公司)的顾问;自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员;从2011年3月到2019年12月,CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。


J. David Joyner,has served as President and CEO of CVS Health since October 2024, having previously held executive roles including EVP of Pharmacy Services (2023-2024) and EVP of Sales and Account Services (2004-2019). He began his career at Caremark Prescription Services in 1993 after starting at Aetna. With 37 years of healthcare and PBM experience, Mr. Joyner holds a BS from Texas Tech University and serves on its Rawls College of Business Advisory Council.
J. David Joyner,自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官;从2023年1月到2024年10月,担任Cvs Health Corporation的执行副总裁兼药房服务总裁;从2021年7月到2023年9月担任健康技术公司gWell, Inc.的战略业务顾问;从2020年9月到2023年1月,担任Podimetrics Inc.(一家专注于糖尿病足溃疡识别和治疗的医疗保健公司)的顾问;自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员;从2011年3月到2019年12月,CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。
J. David Joyner,has served as President and CEO of CVS Health since October 2024, having previously held executive roles including EVP of Pharmacy Services (2023-2024) and EVP of Sales and Account Services (2004-2019). He began his career at Caremark Prescription Services in 1993 after starting at Aetna. With 37 years of healthcare and PBM experience, Mr. Joyner holds a BS from Texas Tech University and serves on its Rawls College of Business Advisory Council.
Guy Sansone

Guy Sansone,独立董事。他是H2 Health的联合创始人、董事长和首席执行官。他一直担任CVS Health董事(2024年11月以来)。此前,他曾担任纽约Alvarez & Marsal的董事总经理。他是几家公开交易和私人持有的医疗保健公司的董事会成员。他持有Albany, SUNY大学的学士学位。


Guy Sansone,is an Independent Director. He is the Co - Founder, Chairman, and Chief Executive Officer of H2 Health. He has been a CVS Health director since November 2024. He previously served as Managing Director at Alvarez & Marsal in New York. He is a member of the boards of several publicly traded and privately held health care companies. He holds a B.S. from the University at Albany, SUNY.
Guy Sansone,独立董事。他是H2 Health的联合创始人、董事长和首席执行官。他一直担任CVS Health董事(2024年11月以来)。此前,他曾担任纽约Alvarez & Marsal的董事总经理。他是几家公开交易和私人持有的医疗保健公司的董事会成员。他持有Albany, SUNY大学的学士学位。
Guy Sansone,is an Independent Director. He is the Co - Founder, Chairman, and Chief Executive Officer of H2 Health. He has been a CVS Health director since November 2024. He previously served as Managing Director at Alvarez & Marsal in New York. He is a member of the boards of several publicly traded and privately held health care companies. He holds a B.S. from the University at Albany, SUNY.
Alecia A. DeCoudreaux

Alecia A. DeCoudreaux自2011年7月以来是Mills College(男性和女性研究生项目的女性文理学院)的总裁。此前,她在Eli Lilly and Company(Eli Lilly)(全球药品制造商)担任许多领导角色,包括专业法律团队的副总裁和副总法律顾问(从2010年到2011年),Lilly美国的副总裁兼总法律顾问(从2005年到2009年),Eli Lilly的秘书、副总法律顾问(从1999年到2005年)。在Eli Lilly的30年职业生涯中,她也曾担任Lilly Research Laboratories的执行董事,联邦政府关系的主管,国家政府关系的主管和社区关系的主管。此外,她曾服务于一些慈善、教育、盈利和非盈利董事会,包括担任Wellesley College的理事和董事会主席。


Alecia A. DeCoudreaux,served as President of Mills College (2011-2016) after a 30-year career at Eli Lilly and Company, where she held executive roles including VP/Deputy General Counsel and VP/General Counsel of Lilly USA. She currently serves as Lead Independent Trustee of Parnassus Funds and previously chaired Wellesley College's board. Ms. DeCoudreaux holds a BA from Wellesley College and JD from Indiana University Maurer School of Law.
Alecia A. DeCoudreaux自2011年7月以来是Mills College(男性和女性研究生项目的女性文理学院)的总裁。此前,她在Eli Lilly and Company(Eli Lilly)(全球药品制造商)担任许多领导角色,包括专业法律团队的副总裁和副总法律顾问(从2010年到2011年),Lilly美国的副总裁兼总法律顾问(从2005年到2009年),Eli Lilly的秘书、副总法律顾问(从1999年到2005年)。在Eli Lilly的30年职业生涯中,她也曾担任Lilly Research Laboratories的执行董事,联邦政府关系的主管,国家政府关系的主管和社区关系的主管。此外,她曾服务于一些慈善、教育、盈利和非盈利董事会,包括担任Wellesley College的理事和董事会主席。
Alecia A. DeCoudreaux,served as President of Mills College (2011-2016) after a 30-year career at Eli Lilly and Company, where she held executive roles including VP/Deputy General Counsel and VP/General Counsel of Lilly USA. She currently serves as Lead Independent Trustee of Parnassus Funds and previously chaired Wellesley College's board. Ms. DeCoudreaux holds a BA from Wellesley College and JD from Indiana University Maurer School of Law.
Leslie Norwalk

Leslie Norwalk,非独立董事。她是Epstein, Becker & Green, P.C。的战略顾问,并自2024年11月起担任CVS Health的董事。她在医疗保健行业以及相关的政府法规、公司治理、医疗保健合规和风险管理方面拥有深厚的知识和经验。她是几家公司的董事会成员,包括Arvinas, Inc., ModivCare, Inc., Neurocrine Biosciences, Inc.和Globus Medical, Inc.。她持有Wellesley College的学士学位和George Mason大学的法学博士学位。


Leslie Norwalk,is a Non - Independent Director. She is a Strategic Counsel at Epstein, Becker & Green, P.C. and has been a CVS Health director since November 2024. She has deep knowledge and experience in the health care industry and related government regulations, corporate governance, health care compliance, and risk management. She sits on the boards of several companies including Arvinas, Inc., ModivCare, Inc., Neurocrine Biosciences, Inc., and Globus Medical, Inc. She holds a B.A. from Wellesley College and a J.D. from George Mason University.
Leslie Norwalk,非独立董事。她是Epstein, Becker & Green, P.C。的战略顾问,并自2024年11月起担任CVS Health的董事。她在医疗保健行业以及相关的政府法规、公司治理、医疗保健合规和风险管理方面拥有深厚的知识和经验。她是几家公司的董事会成员,包括Arvinas, Inc., ModivCare, Inc., Neurocrine Biosciences, Inc.和Globus Medical, Inc.。她持有Wellesley College的学士学位和George Mason大学的法学博士学位。
Leslie Norwalk,is a Non - Independent Director. She is a Strategic Counsel at Epstein, Becker & Green, P.C. and has been a CVS Health director since November 2024. She has deep knowledge and experience in the health care industry and related government regulations, corporate governance, health care compliance, and risk management. She sits on the boards of several companies including Arvinas, Inc., ModivCare, Inc., Neurocrine Biosciences, Inc., and Globus Medical, Inc. She holds a B.A. from Wellesley College and a J.D. from George Mason University.
Larry Robbins

Larry Robbins,是一名独立董事。他是Glenview Capital Management, LLC的创始人兼首席执行官。自2024年11月以来,他一直担任CVS Health的董事。此前,他在Omega Advisors担任了6年的分析师和合伙人。他于2000年创立了Glenview。自2021年以来,他一直担任Butterfly Network, Inc.的首席独立董事和董事会成员。他是教育改革的积极支持者,并在多个教育委员会任职。他拥有宾夕法尼亚大学的学士学位。


Larry Robbins,is an Independent Director. He is the Founder and Chief Executive Officer of Glenview Capital Management, LLC. He has been a CVS Health director since November 2024. He previously spent six years as an analyst and partner at Omega Advisors. He founded Glenview in 2000. He has been a lead independent director and board member of Butterfly Network, Inc. since 2021. He is an active supporter of education reform and serves on various educational boards. He holds a B.S. from the University of Pennsylvania.
Larry Robbins,是一名独立董事。他是Glenview Capital Management, LLC的创始人兼首席执行官。自2024年11月以来,他一直担任CVS Health的董事。此前,他在Omega Advisors担任了6年的分析师和合伙人。他于2000年创立了Glenview。自2021年以来,他一直担任Butterfly Network, Inc.的首席独立董事和董事会成员。他是教育改革的积极支持者,并在多个教育委员会任职。他拥有宾夕法尼亚大学的学士学位。
Larry Robbins,is an Independent Director. He is the Founder and Chief Executive Officer of Glenview Capital Management, LLC. He has been a CVS Health director since November 2024. He previously spent six years as an analyst and partner at Omega Advisors. He founded Glenview in 2000. He has been a lead independent director and board member of Butterfly Network, Inc. since 2021. He is an active supporter of education reform and serves on various educational boards. He holds a B.S. from the University of Pennsylvania.
Doug Shulman

Doug Shulman,独立董事。他是OneMain Holdings, Inc.的董事长兼首席执行官,自2024年11月起担任CVS Health董事。他曾在纽约梅隆银行、麦肯锡公司和美国金融业监管局担任领导职务。他持有Williams College的学士学位,Harvard JFK政府学院的硕士学位,以及Georgetown大学的法学博士学位。


Doug Shulman,is an Independent Director. He is the Chairman and Chief Executive Officer of OneMain Holdings, Inc. and has been a CVS Health director since November 2024. He previously held leadership roles at BNY Mellon, McKinsey & Company, and FINRA. He holds a B.A. from Williams College, an M.P.A. from Harvard JFK School of Government, and a J.D. from Georgetown University.
Doug Shulman,独立董事。他是OneMain Holdings, Inc.的董事长兼首席执行官,自2024年11月起担任CVS Health董事。他曾在纽约梅隆银行、麦肯锡公司和美国金融业监管局担任领导职务。他持有Williams College的学士学位,Harvard JFK政府学院的硕士学位,以及Georgetown大学的法学博士学位。
Doug Shulman,is an Independent Director. He is the Chairman and Chief Executive Officer of OneMain Holdings, Inc. and has been a CVS Health director since November 2024. He previously held leadership roles at BNY Mellon, McKinsey & Company, and FINRA. He holds a B.A. from Williams College, an M.P.A. from Harvard JFK School of Government, and a J.D. from Georgetown University.
Anne M. Finucane

Anne M. Finucane,自2022年起担任Rubicon Carbon主席和TPG气候基金高级顾问,此前她曾担任美国银行副董事长(2015-2021年),领导ESG和可持续金融倡议。她目前在西维斯健康和威廉索诺玛的董事会任职(自2011年起)。Finucane女士拥有新罕布什尔大学的学士学位。


Anne M. Finucane,serves as Chair of Rubicon Carbon and Senior Advisor to TPG Climate Fund since 2022, following her tenure as Vice Chairman of Bank of America (2015-2021) where she led ESG and sustainable finance initiatives. She currently serves on the boards of CVS Health (since 2011) and Williams-Sonoma. Ms. Finucane holds a BA from the University of New Hampshire.
Anne M. Finucane,自2022年起担任Rubicon Carbon主席和TPG气候基金高级顾问,此前她曾担任美国银行副董事长(2015-2021年),领导ESG和可持续金融倡议。她目前在西维斯健康和威廉索诺玛的董事会任职(自2011年起)。Finucane女士拥有新罕布什尔大学的学士学位。
Anne M. Finucane,serves as Chair of Rubicon Carbon and Senior Advisor to TPG Climate Fund since 2022, following her tenure as Vice Chairman of Bank of America (2015-2021) where she led ESG and sustainable finance initiatives. She currently serves on the boards of CVS Health (since 2011) and Williams-Sonoma. Ms. Finucane holds a BA from the University of New Hampshire.
Fernando Aguirre

Fernando Aguirre,自2019年7月起担任董事。2004年1月至2012年10月,他担任Chiquita Brands International, Inc.的总裁兼首席执行官;2004年5月至2012年10月,他担任董事长。在此之前,他从1980年到2004年在宝洁公司担任各种全球营销和管理职务。他目前是CVS Health(一家上市的美国医疗保健公司,拥有CVS Pharmacy、CVS Caremark和Aetna)的董事会成员;百乐嘉利宝是一家上市公司,是世界上最大的可可加工商和巧克力制造商之一。他曾任职于其他董事会,包括Aetna, Inc., Coca-Cola Enterprises和Levi Strauss & Co.。Aguirre先生目前是Erie seawwolves Minor League棒球队(底特律老虎队的双AA附属球队)的所有者和首席执行官。他还拥有默特尔比奇鹈鹕队(Myrtle Beach Pelicans)的少数股权,这是芝加哥小熊队(Chicago Cubs)的低a级球队。Aguirre先生是墨西哥人,是西班牙裔社区的杰出人物,被西班牙裔商业杂志评为100位影响力人物之一,并被NFL授予西班牙裔传统领导奖。他持有Southern Illinois University Edwardsville的学士学位。


Fernando Aguirre,served as Chairman, President and CEO of Chiquita Brands International (2004-2012) after a 23-year career at Procter & Gamble where he held leadership roles including President of P&G Mexico and VP of global snacks. He currently serves on the boards of CVS Health (since 2018), Barry Callebaut AG, and Synchrony Financial. Aguirre holds a BS from Southern Illinois University Edwardsville.
Fernando Aguirre,自2019年7月起担任董事。2004年1月至2012年10月,他担任Chiquita Brands International, Inc.的总裁兼首席执行官;2004年5月至2012年10月,他担任董事长。在此之前,他从1980年到2004年在宝洁公司担任各种全球营销和管理职务。他目前是CVS Health(一家上市的美国医疗保健公司,拥有CVS Pharmacy、CVS Caremark和Aetna)的董事会成员;百乐嘉利宝是一家上市公司,是世界上最大的可可加工商和巧克力制造商之一。他曾任职于其他董事会,包括Aetna, Inc., Coca-Cola Enterprises和Levi Strauss & Co.。Aguirre先生目前是Erie seawwolves Minor League棒球队(底特律老虎队的双AA附属球队)的所有者和首席执行官。他还拥有默特尔比奇鹈鹕队(Myrtle Beach Pelicans)的少数股权,这是芝加哥小熊队(Chicago Cubs)的低a级球队。Aguirre先生是墨西哥人,是西班牙裔社区的杰出人物,被西班牙裔商业杂志评为100位影响力人物之一,并被NFL授予西班牙裔传统领导奖。他持有Southern Illinois University Edwardsville的学士学位。
Fernando Aguirre,served as Chairman, President and CEO of Chiquita Brands International (2004-2012) after a 23-year career at Procter & Gamble where he held leadership roles including President of P&G Mexico and VP of global snacks. He currently serves on the boards of CVS Health (since 2018), Barry Callebaut AG, and Synchrony Financial. Aguirre holds a BS from Southern Illinois University Edwardsville.
Roger N. Farah

Roger N. Farah,自2024年10月起担任Cvs Health Corporation董事会执行主席;自2022年5月起担任Cvs Health Corporation董事会主席;自2018年11月起担任Cvs Health Corporation的董事;2007年6月至2018年11月担任Aetna, Inc.的董事。他目前还担任The Progressive Corporation(一家汽车保险公司)的董事,并曾担任Tiffany & Co.的董事会主席和董事(直到2021年1月),以及Metro Bank PLC的董事(直到2020年3月)。


Roger N. Farah,has served as Executive Chair of CVS Health since 2024, having previously served as Independent Chair (2022-2024). His retail leadership includes roles as Chairman of Tiffany & Co. (2017-2021), Executive Director of Tory Burch (2014-2017), and EVP/COO of Ralph Lauren (2000-2013). He currently serves on Progressive Corporation's board and previously served on Aetna's board until its CVS acquisition. Mr. Farah holds a BS from the University of Pennsylvania.
Roger N. Farah,自2024年10月起担任Cvs Health Corporation董事会执行主席;自2022年5月起担任Cvs Health Corporation董事会主席;自2018年11月起担任Cvs Health Corporation的董事;2007年6月至2018年11月担任Aetna, Inc.的董事。他目前还担任The Progressive Corporation(一家汽车保险公司)的董事,并曾担任Tiffany & Co.的董事会主席和董事(直到2021年1月),以及Metro Bank PLC的董事(直到2020年3月)。
Roger N. Farah,has served as Executive Chair of CVS Health since 2024, having previously served as Independent Chair (2022-2024). His retail leadership includes roles as Chairman of Tiffany & Co. (2017-2021), Executive Director of Tory Burch (2014-2017), and EVP/COO of Ralph Lauren (2000-2013). He currently serves on Progressive Corporation's board and previously served on Aetna's board until its CVS acquisition. Mr. Farah holds a BS from the University of Pennsylvania.
C. David Brown II

C. David Brown II,自2000年3月起担任Broad and Cassel(佛罗里达州律师事务所)的董事长。从1989年到2000年3月,他是公司奥兰多办事处的管理合伙人。他也是Rayonier Advanced Materials Inc.的首席董事。RYAM是一家领先的特种纤维素生产公司。他曾担任Rayonier Inc.(一家房地产开发和林地管理公司)的董事会成员和首席董事(2014年6月RYAM分拆之前)。从2015年4月到2016年9月,他还担任ITT Educational Services, Inc.(一个面向技术的本科和研究生学位课程的国家供应商)的董事。2001年3月起,Brown先生担任Caremark Rx, Inc.的董事会成员,直到涉及CVS Health和Caremark的合并交易完成,当时他成为CVS Health的董事。Brown先生拥有佛罗里达大学的博士学位。


C. David Brown II,has been a partner at Nelson Mullins Riley & Scarborough LLP since 2018, previously serving as Chairman of Broad and Cassel until its merger. He served as lead director of Rayonier Advanced Materials until 2020 and has been a CVS Health director since 2007 (originally joining through Caremark Rx's board). Mr. Brown holds a BSBA and JD from the University of Florida.
C. David Brown II,自2000年3月起担任Broad and Cassel(佛罗里达州律师事务所)的董事长。从1989年到2000年3月,他是公司奥兰多办事处的管理合伙人。他也是Rayonier Advanced Materials Inc.的首席董事。RYAM是一家领先的特种纤维素生产公司。他曾担任Rayonier Inc.(一家房地产开发和林地管理公司)的董事会成员和首席董事(2014年6月RYAM分拆之前)。从2015年4月到2016年9月,他还担任ITT Educational Services, Inc.(一个面向技术的本科和研究生学位课程的国家供应商)的董事。2001年3月起,Brown先生担任Caremark Rx, Inc.的董事会成员,直到涉及CVS Health和Caremark的合并交易完成,当时他成为CVS Health的董事。Brown先生拥有佛罗里达大学的博士学位。
C. David Brown II,has been a partner at Nelson Mullins Riley & Scarborough LLP since 2018, previously serving as Chairman of Broad and Cassel until its merger. He served as lead director of Rayonier Advanced Materials until 2020 and has been a CVS Health director since 2007 (originally joining through Caremark Rx's board). Mr. Brown holds a BSBA and JD from the University of Florida.
Michael F. Mahoney

Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。


Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
J. Scott Kirby

J. Scott Kirby,United Airlines Holdings, Inc.:首席执行官(2020年至今)、总裁(2016-2020年);美国航空集团和美国;Airlines,Inc.(航空公司):总裁(2013-2016年);US Airways(航空公司):总裁(2006-2013年)。学历:乔治华盛顿大学,硕士,运筹学、美国空军学院、学士,计算机科学与运筹学。


J. Scott Kirby,is an Independent Director. He has been the Chief Executive Officer and a member of the Board of United Airlines Holdings, Inc. since May 2020. He also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 to May 2020, he was President of United Airlines. Before that, he was President of American Airlines from December 2013 to August 2016 and President of US Airways from September 2006 to December 2013. He started his career at the Pentagon and in the technology sector. He is a member of various airline - related boards and associations. He holds a B.S. from the U.S. Air Force Academy and an M.S. from George Washington University.
J. Scott Kirby,United Airlines Holdings, Inc.:首席执行官(2020年至今)、总裁(2016-2020年);美国航空集团和美国;Airlines,Inc.(航空公司):总裁(2013-2016年);US Airways(航空公司):总裁(2006-2013年)。学历:乔治华盛顿大学,硕士,运筹学、美国空军学院、学士,计算机科学与运筹学。
J. Scott Kirby,is an Independent Director. He has been the Chief Executive Officer and a member of the Board of United Airlines Holdings, Inc. since May 2020. He also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 to May 2020, he was President of United Airlines. Before that, he was President of American Airlines from December 2013 to August 2016 and President of US Airways from September 2006 to December 2013. He started his career at the Pentagon and in the technology sector. He is a member of various airline - related boards and associations. He holds a B.S. from the U.S. Air Force Academy and an M.S. from George Washington University.
Jeffrey R. Balser

Jeffrey R. Balser,2016年起担任范德比尔特大学医学中心总裁兼首席执行官,2008年起担任范德比尔特大学医学院院长。美国国家医学研究院院士,他此前曾担任瓦里安医疗董事会成员(2018-2021年)。Balser博士拥有杜兰大学学士学位和范德比尔特大学医学博士学位。


Jeffrey R. Balser,has served as President and CEO of Vanderbilt University Medical Center since 2016 and Dean of Vanderbilt University School of Medicine since 2008. A member of the National Academy of Medicine, he previously served on the board of Varian Medical Systems (2018-2021). Dr. Balser holds a BS from Tulane University and MD/PhD from Vanderbilt University.
Jeffrey R. Balser,2016年起担任范德比尔特大学医学中心总裁兼首席执行官,2008年起担任范德比尔特大学医学院院长。美国国家医学研究院院士,他此前曾担任瓦里安医疗董事会成员(2018-2021年)。Balser博士拥有杜兰大学学士学位和范德比尔特大学医学博士学位。
Jeffrey R. Balser,has served as President and CEO of Vanderbilt University Medical Center since 2016 and Dean of Vanderbilt University School of Medicine since 2008. A member of the National Academy of Medicine, he previously served on the board of Varian Medical Systems (2018-2021). Dr. Balser holds a BS from Tulane University and MD/PhD from Vanderbilt University.

高管简历

中英对照 |  中文 |  英文
J. David Joyner

J. David Joyner,自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官;从2023年1月到2024年10月,担任Cvs Health Corporation的执行副总裁兼药房服务总裁;从2021年7月到2023年9月担任健康技术公司gWell, Inc.的战略业务顾问;从2020年9月到2023年1月,担任Podimetrics Inc.(一家专注于糖尿病足溃疡识别和治疗的医疗保健公司)的顾问;自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员;从2011年3月到2019年12月,CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。


J. David Joyner,has served as President and CEO of CVS Health since October 2024, having previously held executive roles including EVP of Pharmacy Services (2023-2024) and EVP of Sales and Account Services (2004-2019). He began his career at Caremark Prescription Services in 1993 after starting at Aetna. With 37 years of healthcare and PBM experience, Mr. Joyner holds a BS from Texas Tech University and serves on its Rawls College of Business Advisory Council.
J. David Joyner,自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官;从2023年1月到2024年10月,担任Cvs Health Corporation的执行副总裁兼药房服务总裁;从2021年7月到2023年9月担任健康技术公司gWell, Inc.的战略业务顾问;从2020年9月到2023年1月,担任Podimetrics Inc.(一家专注于糖尿病足溃疡识别和治疗的医疗保健公司)的顾问;自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员;从2011年3月到2019年12月,CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。
J. David Joyner,has served as President and CEO of CVS Health since October 2024, having previously held executive roles including EVP of Pharmacy Services (2023-2024) and EVP of Sales and Account Services (2004-2019). He began his career at Caremark Prescription Services in 1993 after starting at Aetna. With 37 years of healthcare and PBM experience, Mr. Joyner holds a BS from Texas Tech University and serves on its Rawls College of Business Advisory Council.
Heidi B. Capozzi

Heidi B. Capozzi, 曾一直担任高级副总裁,负责人力资源(2016年3月以来)。她此前曾担任领导力发展、人才管理和组织有效性副总裁(2013年4月至2016年3月)、Commercial Airplanes的飞机项目部门的人力资源主管(2011年4月至2013年4月)、Boeing Military Aircraft的监督和参与部门的人力资源主管(2009年5月至2011年4月)。


Heidi B. Capozzi previously served as Vice President of Leadership Development, Talent Management and Organization Effectiveness from April 2013 to March 2016; Director of Human Resources for the Airplane Programs division of Commercial Airplanes from April 2011 to April 2013; and Director of Human Resources for the Surveillance and Engagement division of Boeing Military Aircraft from May 2009 to April 2011.
Heidi B. Capozzi, 曾一直担任高级副总裁,负责人力资源(2016年3月以来)。她此前曾担任领导力发展、人才管理和组织有效性副总裁(2013年4月至2016年3月)、Commercial Airplanes的飞机项目部门的人力资源主管(2011年4月至2013年4月)、Boeing Military Aircraft的监督和参与部门的人力资源主管(2009年5月至2011年4月)。
Heidi B. Capozzi previously served as Vice President of Leadership Development, Talent Management and Organization Effectiveness from April 2013 to March 2016; Director of Human Resources for the Airplane Programs division of Commercial Airplanes from April 2011 to April 2013; and Director of Human Resources for the Surveillance and Engagement division of Boeing Military Aircraft from May 2009 to April 2011.
James D. Clark

James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark; 从2009年9月至2018年10月,CVS Pharmacy,Inc.财务和会计副总裁。


James D. Clark,Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.
James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark; 从2009年9月至2018年10月,CVS Pharmacy,Inc.财务和会计副总裁。
James D. Clark,Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.
Prem Shah

Prem Shah,自2024年11月起担任CVS Health Corporation的执行副总裁兼集团总裁;从2021年11月到2024年11月担任CVS Health Corporation的执行副总裁兼首席药房官,从2022年1月到2024年11月担任零售总裁或联席总裁;从2018年8月到2021年11月,CVS Caremark执行副总裁,专业和产品创新;从2013年2月到2018年7月,CVS Caremark担任专业药房副总裁。


Prem Shah,Executive Vice President and Group President of CVS Health Corporation since November 2024; Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation from November 2021 through November 2024 and President or Co-President of Retail from January 2022 through November 2024; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
Prem Shah,自2024年11月起担任CVS Health Corporation的执行副总裁兼集团总裁;从2021年11月到2024年11月担任CVS Health Corporation的执行副总裁兼首席药房官,从2022年1月到2024年11月担任零售总裁或联席总裁;从2018年8月到2021年11月,CVS Caremark执行副总裁,专业和产品创新;从2013年2月到2018年7月,CVS Caremark担任专业药房副总裁。
Prem Shah,Executive Vice President and Group President of CVS Health Corporation since November 2024; Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation from November 2021 through November 2024 and President or Co-President of Retail from January 2022 through November 2024; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
Tilak Mandadi

Tilak Mandadi,自2022年7月起担任CVS Health Corporation的风险投资执行副总裁兼首席数字、数据、分析和技术官;2021年7月至2022年7月,担任MGM Resorts International首席战略官;2013年3月至2021年7月,担任迪士尼乐园、体验和产品的执行副总裁、数字和全球首席技术官。


Tilak Mandadi,Executive Vice President, Ventures and Chief Digital, Data, Analytics and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.
Tilak Mandadi,自2022年7月起担任CVS Health Corporation的风险投资执行副总裁兼首席数字、数据、分析和技术官;2021年7月至2022年7月,担任MGM Resorts International首席战略官;2013年3月至2021年7月,担任迪士尼乐园、体验和产品的执行副总裁、数字和全球首席技术官。
Tilak Mandadi,Executive Vice President, Ventures and Chief Digital, Data, Analytics and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.
Thomas F. Cowhey

Thomas F. Cowhey,自2022年2月加入公司以来,他一直担任Cvs Health Corporation资本市场高级副总裁,最近扩大了他的角色,包括监督更广泛的公司财务职能。在加入CVS Health之前,Cowhey先生从2018年4月到2022年2月担任医疗服务公司Surgery Partners的执行副总裁兼首席财务官。在此之前,他曾在Aetna、Legacy Partners Group和Credit Suisse的医疗保健和并购集团担任领导职务。


Thomas F. Cowhey,Executive Vice President and Chief Financial Officer of CVS Health Corporation since January 2024; Senior Vice President and Interim Chief Financial Officer of CVS Health Corporation from October 2023 through January 2024; Senior Vice President, Corporate Finance of CVS Health Corporation from September 2023 through October 2023; Senior Vice President, Capital Markets of CVS Health Corporation from February 2022 through September 2023; and Executive Vice President and Chief Financial Officer of Surgical Partners, a large independent operator of short-stay surgical facilities, from April 2018 through February 2022.
Thomas F. Cowhey,自2022年2月加入公司以来,他一直担任Cvs Health Corporation资本市场高级副总裁,最近扩大了他的角色,包括监督更广泛的公司财务职能。在加入CVS Health之前,Cowhey先生从2018年4月到2022年2月担任医疗服务公司Surgery Partners的执行副总裁兼首席财务官。在此之前,他曾在Aetna、Legacy Partners Group和Credit Suisse的医疗保健和并购集团担任领导职务。
Thomas F. Cowhey,Executive Vice President and Chief Financial Officer of CVS Health Corporation since January 2024; Senior Vice President and Interim Chief Financial Officer of CVS Health Corporation from October 2023 through January 2024; Senior Vice President, Corporate Finance of CVS Health Corporation from September 2023 through October 2023; Senior Vice President, Capital Markets of CVS Health Corporation from February 2022 through September 2023; and Executive Vice President and Chief Financial Officer of Surgical Partners, a large independent operator of short-stay surgical facilities, from April 2018 through February 2022.
Roger N. Farah

Roger N. Farah,自2024年10月起担任Cvs Health Corporation董事会执行主席;自2022年5月起担任Cvs Health Corporation董事会主席;自2018年11月起担任Cvs Health Corporation的董事;2007年6月至2018年11月担任Aetna, Inc.的董事。他目前还担任The Progressive Corporation(一家汽车保险公司)的董事,并曾担任Tiffany & Co.的董事会主席和董事(直到2021年1月),以及Metro Bank PLC的董事(直到2020年3月)。


Roger N. Farah,has served as Executive Chair of CVS Health since 2024, having previously served as Independent Chair (2022-2024). His retail leadership includes roles as Chairman of Tiffany & Co. (2017-2021), Executive Director of Tory Burch (2014-2017), and EVP/COO of Ralph Lauren (2000-2013). He currently serves on Progressive Corporation's board and previously served on Aetna's board until its CVS acquisition. Mr. Farah holds a BS from the University of Pennsylvania.
Roger N. Farah,自2024年10月起担任Cvs Health Corporation董事会执行主席;自2022年5月起担任Cvs Health Corporation董事会主席;自2018年11月起担任Cvs Health Corporation的董事;2007年6月至2018年11月担任Aetna, Inc.的董事。他目前还担任The Progressive Corporation(一家汽车保险公司)的董事,并曾担任Tiffany & Co.的董事会主席和董事(直到2021年1月),以及Metro Bank PLC的董事(直到2020年3月)。
Roger N. Farah,has served as Executive Chair of CVS Health since 2024, having previously served as Independent Chair (2022-2024). His retail leadership includes roles as Chairman of Tiffany & Co. (2017-2021), Executive Director of Tory Burch (2014-2017), and EVP/COO of Ralph Lauren (2000-2013). He currently serves on Progressive Corporation's board and previously served on Aetna's board until its CVS acquisition. Mr. Farah holds a BS from the University of Pennsylvania.
Steven H. Nelson

Steven H. Nelson自2010年11月起担任公司董事。Nelson自2008年8月起担任West Region of UnitedHealthCare(UnitedHealth Group一个运营分部,健康福利和服务供应商)首席执行官。Nelson从2007年12月到2008年8月担任AmeriChoice(UnitedHealth Group一家子公司)总裁。他从2004年10月到2007年12月担任HealthNet(一家医疗保健公司)东部地区总裁和高级产品分部总裁。Nelson从1998年6月到1998年12月在Henry Ford Health System(一家非盈利组织)担任多个执行职位。Nelson持有Portland State University文学学士学位;the University of Michigan工商管理和医疗保健管理硕士学位。


Steven H. Nelson is Executive Vice President of UnitedHealth Group and Chief Executive Officer of UnitedHealthcare and has served in that capacity since August 2017. Mr. Nelson served as Chief Executive Officer of UnitedHealthcare’s Medicare & Retirement, from March 2014 to August 2017. He served as Chief Executive Officer of UnitedHealthcare Community & State from August 2012 to March 2014. From January 2008 to July 2012 he served as President of UnitedHealthcare Community & State and then Chief Executive Officer of UnitedHealthcare Employer & Individual’s West Region business.
Steven H. Nelson自2010年11月起担任公司董事。Nelson自2008年8月起担任West Region of UnitedHealthCare(UnitedHealth Group一个运营分部,健康福利和服务供应商)首席执行官。Nelson从2007年12月到2008年8月担任AmeriChoice(UnitedHealth Group一家子公司)总裁。他从2004年10月到2007年12月担任HealthNet(一家医疗保健公司)东部地区总裁和高级产品分部总裁。Nelson从1998年6月到1998年12月在Henry Ford Health System(一家非盈利组织)担任多个执行职位。Nelson持有Portland State University文学学士学位;the University of Michigan工商管理和医疗保健管理硕士学位。
Steven H. Nelson is Executive Vice President of UnitedHealth Group and Chief Executive Officer of UnitedHealthcare and has served in that capacity since August 2017. Mr. Nelson served as Chief Executive Officer of UnitedHealthcare’s Medicare & Retirement, from March 2014 to August 2017. He served as Chief Executive Officer of UnitedHealthcare Community & State from August 2012 to March 2014. From January 2008 to July 2012 he served as President of UnitedHealthcare Community & State and then Chief Executive Officer of UnitedHealthcare Employer & Individual’s West Region business.
Samrat S. Khichi

Samrat S. Khichi,自2023年2月起担任CVS Health Corporation的执行副总裁、首席政策官和总法律顾问;从2017年12月到2023年2月,担任全球医疗技术公司Becton Dickinson Company(“BD”)的执行副总裁,负责企业发展、公共政策、监管事务和总法律顾问;从2014年7月到2017年12月,担任C.R. Bard(一家从BD收购的医疗技术公司)的高级副总裁、总法律顾问兼秘书。


Samrat S. Khichi,Executive Vice President, Chief Policy Officer and General Counsel of CVS Health Corporation since February 2023; Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel of Becton Dickinson Company ("BD"), a global medical technology company, from December 2017 through February 2023; Senior Vice President, General Counsel and Secretary of C.R. Bard, a medical technology company that was acquired from BD, from July 2014 through December 2017.
Samrat S. Khichi,自2023年2月起担任CVS Health Corporation的执行副总裁、首席政策官和总法律顾问;从2017年12月到2023年2月,担任全球医疗技术公司Becton Dickinson Company(“BD”)的执行副总裁,负责企业发展、公共政策、监管事务和总法律顾问;从2014年7月到2017年12月,担任C.R. Bard(一家从BD收购的医疗技术公司)的高级副总裁、总法律顾问兼秘书。
Samrat S. Khichi,Executive Vice President, Chief Policy Officer and General Counsel of CVS Health Corporation since February 2023; Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel of Becton Dickinson Company ("BD"), a global medical technology company, from December 2017 through February 2023; Senior Vice President, General Counsel and Secretary of C.R. Bard, a medical technology company that was acquired from BD, from July 2014 through December 2017.